CARISMA Therapeutics Plunges 10.36% Amid Market Volatility

On June 20, 2025, CARISMA Therapeutics experienced a significant drop of 10.36% in pre-market trading, marking a notable decline in its stock performance.

Analysts covering CARISMA Therapeutics have a consensus rating of "Hold" with an average price target of $0.90, indicating a potential 79.18% increase from its current price. This suggests that while there is optimism about the company's future, the recent drop may be due to short-term market fluctuations or investor sentiment.

CARISMA Therapeutics is a biotechnology company focused on developing innovative protein-based therapeutics to treat diseases with unmet needs, such as inflammatory conditions and coagulation disorders. The company's unique molecular understanding and engineering capabilities position it well in the competitive biotech landscape.

The recent decline in stock price could be attributed to various factors, including market volatility, investor reactions to recent news, or adjustments in analyst ratings. However, the company's long-term prospects remain promising, given its focus on cutting-edge research and development in the biotech sector.